Literature DB >> 19351863

Src-Induced cisplatin resistance mediated by cell-to-cell communication.

Elizabeth Peterson-Roth1, Cathleen M Brdlik, Peter M Glazer.   

Abstract

Cisplatin-induced cell death can be triggered by cell-to-cell communication through gap junctions. Here, we show that activated src produces tyrosine phosphorylation of the gap junction protein connexin 43, decreases gap junction communication, and increases cell survival in response to cisplatin. Experiments with mixed cell populations show that src activity in one cell can confer increased cisplatin survival on neighboring cells, even when the neighboring cells lack such src activity. This work is the first demonstration that expression of an oncogene in one cell can affect the survival of a neighboring cell not expressing the oncogene in response to a chemotherapeutic drug. The trans-acting effect of activated src on neighboring cells can be blocked by inhibitors of src kinase or by siRNA-mediated knockdown of src expression, and it can be counteracted by forced up-regulation of connexin 43, via either gene transfer or proteasome inhibition. These results identify a novel pathway of cisplatin resistance that may be amenable to therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351863      PMCID: PMC2972619          DOI: 10.1158/0008-5472.CAN-08-0985

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Gap-junctional coupling measured by flow cytometry.

Authors:  J Czyz; U Irmer; G Schulz; A Mindermann; D F Hülser
Journal:  Exp Cell Res       Date:  2000-02-25       Impact factor: 3.905

2.  Regulation of connexin degradation as a mechanism to increase gap junction assembly and function.

Authors:  L S Musil; A C Le; J K VanSlyke; L M Roberts
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

3.  Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression.

Authors:  T J King; L H Fukushima; A D Hieber; K A Shimabukuro; W A Sakr; J S Bertram
Journal:  Carcinogenesis       Date:  2000-06       Impact factor: 4.944

4.  Correlation of increased levels of Ha-ras T24 protein with extent of loss of gap junction function in rat liver epithelial cells.

Authors:  A W de Feijter; J E Trosko; D B Krizman; R M Lebovitz; M W Lieberman
Journal:  Mol Carcinog       Date:  1992       Impact factor: 4.784

5.  Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

Authors:  M E Gorre; M Mohammed; K Ellwood; N Hsu; R Paquette; P N Rao; C L Sawyers
Journal:  Science       Date:  2001-06-21       Impact factor: 47.728

6.  Expression of pp60c-src in human small cell and non-small cell lung carcinomas.

Authors:  N N Mazurenko; E A Kogan; I B Zborovskaya; F L Kisseljov
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

7.  Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions.

Authors:  Ryan Jensen; Peter M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

8.  Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.

Authors:  Yolande Pengetnze; Mary Steed; Katherine F Roby; Paul F Terranova; Christopher C Taylor
Journal:  Biochem Biophys Res Commun       Date:  2003-09-19       Impact factor: 3.575

9.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.

Authors:  Jon R Wiener; T Christopher Windham; Veronica C Estrella; Nila U Parikh; Peter F Thall; Michael T Deavers; Robert C Bast; Gordon B Mills; Gary E Gallick
Journal:  Gynecol Oncol       Date:  2003-01       Impact factor: 5.482

10.  v-Src phosphorylation of connexin 43 on Tyr247 and Tyr265 disrupts gap junctional communication.

Authors:  R Lin; B J Warn-Cramer; W E Kurata; A F Lau
Journal:  J Cell Biol       Date:  2001-08-20       Impact factor: 10.539

View more
  18 in total

1.  Targeting SRC in mucinous ovarian carcinoma.

Authors:  Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

2.  Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells.

Authors:  Ying Ding; Thu Annelise Nguyen
Journal:  J Cancer Sci Ther       Date:  2012-11-01

3.  New Mandelalides Expand a Macrolide Series of Mitochondrial Inhibitors.

Authors:  Mohamad Nazari; Jeffrey D Serrill; Xuemei Wan; Minh H Nguyen; Clemens Anklin; David A Gallegos; Amos B Smith; Jane E Ishmael; Kerry L McPhail
Journal:  J Med Chem       Date:  2017-09-07       Impact factor: 7.446

Review 4.  The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.

Authors:  Christopher Lieu; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2010-04       Impact factor: 4.481

5.  Hyperphosphorylation of HDAC2 promotes drug resistance in a novel dual drug resistant mouse melanoma cell line model: an in vitro study.

Authors:  Bhuvanesh Sukhlal Kalal; Prashant Kumar Modi; Mohd Altaf Najar; Santosh Kumar Behera; Dinesh Upadhya; Thottethodi Subrahmanya Keshava Prasad; Vinitha Ramanath Pai
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

6.  Targeting SRC and tubulin in mucinous ovarian carcinoma.

Authors:  Tao Liu; Wei Hu; Heather J Dalton; Hyun Jin Choi; Jie Huang; Yu Kang; Sunila Pradeep; Takahito Miyake; Jian H Song; Yunfei Wen; Chunhua Lu; Chad V Pecot; Justin Bottsford-Miller; Behrouz Zand; Nicholas B Jennings; Cristina Ivan; Gary E Gallick; Keith A Baggerly; David G Hangauer; Robert L Coleman; Michael Frumovitz; Anil K Sood
Journal:  Clin Cancer Res       Date:  2013-10-07       Impact factor: 12.531

7.  Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells.

Authors:  Priya Samuel; Laura Ann Mulcahy; Fiona Furlong; Helen O McCarthy; Susan Ann Brooks; Muller Fabbri; Ryan Charles Pink; David Raul Francisco Carter
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-01-05       Impact factor: 6.237

8.  Gap junction enhancer increases efficacy of cisplatin to attenuate mammary tumor growth.

Authors:  Stephanie N Shishido; Thu A Nguyen
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB.

Authors:  Karen E Eberle; Hope A Sansing; Peter Szaniszlo; Vicente A Resto; Allison L Berrier
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

10.  Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.

Authors:  S Kaye; S Aamdal; R Jones; G Freyer; E Pujade-Lauraine; E G E de Vries; J Barriuso; S Sandhu; D S-W Tan; V Hartog; B Kuenen; R Ruijter; G B Kristensen; M Nyakas; S Barrett; W Burke; D Pietersma; M Stuart; U Emeribe; E Boven
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.